| Literature DB >> 27083101 |
David I Bernstein1, Gene Schwartz2, Jonathan A Bernstein2.
Abstract
The prevalence of allergic rhinitis (AR) has been estimated at 10% to 40%, and its economic burden is substantial. AR patients develop specific immunoglobulin E (IgE) antibody responses to indoor and outdoor environmental allergens with exposure over time. These specific IgE antibodies bind to high-affinity IgE receptors on mast cells and basophils. Key outcome measures of therapeutic interventions include rhinitis symptom control, rescue medication requirements, and quality-of-life measures. A comprehensive multiple modality treatment plan customized to the individual patient can optimize outcomes.Entities:
Keywords: Allergic rhinitis treatment; Intranasal antihistamines; Intranasal corticosteroids; Leukotrienes; Mechanisms; Subcutaneous immunotherapy; Treatment
Mesh：
Year: 2016 PMID： 27083101 DOI： 10.1016/j.iac.2015.12.004
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN： 0889-8561 Impact factor: 3.479